[go: up one dir, main page]

CL2008001332A1 - Uso de temozolomida para preparar un medicamento util para el tratamiento de un desorden proliferativo. - Google Patents

Uso de temozolomida para preparar un medicamento util para el tratamiento de un desorden proliferativo.

Info

Publication number
CL2008001332A1
CL2008001332A1 CL2008001332A CL2008001332A CL2008001332A1 CL 2008001332 A1 CL2008001332 A1 CL 2008001332A1 CL 2008001332 A CL2008001332 A CL 2008001332A CL 2008001332 A CL2008001332 A CL 2008001332A CL 2008001332 A1 CL2008001332 A1 CL 2008001332A1
Authority
CL
Chile
Prior art keywords
temozolomide
proliferative disorder
prepare
treatment
drug useful
Prior art date
Application number
CL2008001332A
Other languages
English (en)
Inventor
Malaz Abutarif
Paul Statkevich
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of CL2008001332A1 publication Critical patent/CL2008001332A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Método para tratar un paciente que tiene un desorden proliferativo que comprende la administración de una formulación que comprende temozolomida o una sal de la misma, donde la formulación es administrada por infusión intravenosa durante un período de aproximadamente 1 hora a aproximadamente 2 horas; producto de la droga.
CL2008001332A 2007-05-08 2008-05-07 Uso de temozolomida para preparar un medicamento util para el tratamiento de un desorden proliferativo. CL2008001332A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91662207P 2007-05-08 2007-05-08
US1374307P 2007-12-14 2007-12-14

Publications (1)

Publication Number Publication Date
CL2008001332A1 true CL2008001332A1 (es) 2009-01-02

Family

ID=39643416

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008001332A CL2008001332A1 (es) 2007-05-08 2008-05-07 Uso de temozolomida para preparar un medicamento util para el tratamiento de un desorden proliferativo.

Country Status (13)

Country Link
US (1) US20100210700A1 (es)
EP (2) EP2157972A1 (es)
JP (1) JP2010526809A (es)
CN (1) CN101678002A (es)
AU (1) AU2008251921A1 (es)
BR (1) BRPI0823416A2 (es)
CA (1) CA2686848A1 (es)
CL (1) CL2008001332A1 (es)
MX (1) MX2009012054A (es)
NZ (1) NZ580982A (es)
TW (1) TW200845962A (es)
WO (1) WO2008140724A1 (es)
ZA (1) ZA200907834B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011036676A2 (en) 2009-09-23 2011-03-31 Ashwini Nangia Stable cocrystals of temozolomide
WO2011077458A1 (en) * 2009-12-23 2011-06-30 Sahaj Life Sciences Pvt. Ltd. Formulations of temozolomide for parenteral administration
CN103108636A (zh) * 2010-02-26 2013-05-15 尼基制药公司 治疗脑癌的方法
CN101869551B (zh) * 2010-06-28 2012-04-18 江苏奥赛康药业股份有限公司 一种替莫唑胺冻干制剂
CN102949350A (zh) * 2011-08-16 2013-03-06 上海汇伦生命科技有限公司 一种替莫唑胺的冻干制剂及其制备方法
US8974811B2 (en) 2013-03-14 2015-03-10 Hikma Pharmaceuticals Stabilized pharmaceutical formulations comprising antineoplastic compounds
CN103147830B (zh) * 2013-03-26 2016-09-28 凯龙高科技股份有限公司 一种scr尾气后处理系统故障诊断仪

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4455256A (en) * 1981-05-05 1984-06-19 The Regents Of The University Of California Bone morphogenetic protein
US5260291A (en) 1981-08-24 1993-11-09 Cancer Research Campaign Technology Limited Tetrazine derivatives
US5731304A (en) * 1982-08-23 1998-03-24 Cancer Research Campaign Technology Potentiation of temozolomide in human tumour cells
JPS60243028A (ja) * 1984-04-28 1985-12-03 Kyowa Hakko Kogyo Co Ltd インタ−フエロンの可溶化方法
US5268368A (en) * 1991-05-17 1993-12-07 Erbamont, Inc. Cyclophosphamide--amino acid lyophilizates
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
US5407804A (en) 1992-05-22 1995-04-18 Applied Genetics Inc. Assays for O6 -methylguanine-DNA methyltransferase
GB9224888D0 (en) 1992-11-27 1993-01-13 Univ Singapore Monoclonal antibody
US5786146A (en) 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US5942247A (en) * 1996-07-31 1999-08-24 Schering Corporation Method for treating pediatric high grade astrocytoma including brain stem glioma
US5824346A (en) 1996-08-22 1998-10-20 Schering Corporation Combination therapy for advanced cancer
US5939098A (en) 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
GB9722320D0 (en) 1997-10-22 1997-12-17 Janssen Pharmaceutica Nv Human cell cycle checkpoint proteins
WO1999030710A1 (en) 1997-12-13 1999-06-24 Bristol-Myers Squibb Company USE OF PYRAZOLO [3,4-b] PYRIDINE AS CYCLIN DEPENDENT KINASE INHIBITORS
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
US6383744B1 (en) 1998-07-10 2002-05-07 Incyte Genomics, Inc. Human checkpoint kinase
EP1135135A4 (en) 1998-09-18 2006-08-09 Smithkline Beecham Corp CHK1 KINASE INHIBITORS
US6251886B1 (en) 1998-12-07 2001-06-26 Schering Corporation Methods of using temozolomide in the treatment of cancers
US6346524B1 (en) 1999-03-30 2002-02-12 Schering Corporation Cancer treatment with temozolomide
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
US6331393B1 (en) 1999-05-14 2001-12-18 University Of Southern California Process for high-throughput DNA methylation analysis
ATE388226T1 (de) 1999-08-27 2008-03-15 Novartis Vaccines & Diagnostic Chimerische antisense-oligonukleotide und zelltransfektions-zusammensetzungen davon
EP1218494B1 (en) 1999-09-22 2005-04-06 Canbas Co., Ltd. Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents
CN1434825A (zh) * 1999-12-24 2003-08-06 拜尔公司 咪唑并[1,3,5]三嗪酮及其应用
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US6211164B1 (en) 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
GB0017508D0 (en) 2000-07-17 2000-08-30 Novartis Ag Antimicrobials
DE10034801A1 (de) 2000-07-18 2002-01-31 Bayer Ag Substituierte Amidoalkyl-uracile und ihre Verwendung
KR20030016429A (ko) 2000-07-26 2003-02-26 브리스톨-마이어스스퀴브컴파니 시클린 의존성 키나제의ｎ-[5-[[[5-알킬-2-옥사졸릴]메틸]티오]-2-티아졸릴]카르복스아미드 저해제
EP1328656A4 (en) 2000-09-29 2005-09-14 Univ Johns Hopkins Med METHOD OF PREDICTING CLINICAL REACTION TO CHEMOTHERAPEUTIC TREATMENT WITH ALKYLATING AGENTS
CA2429437A1 (en) * 2000-11-20 2002-05-23 Takeda Chemical Industries, Ltd. Imidazole derivatives, process for their preparation and their use
US6703400B2 (en) 2001-02-23 2004-03-09 Schering Corporation Methods for treating multidrug resistance
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
BRPI0307802B8 (pt) * 2002-02-22 2021-05-25 Merck Sharp & Dohme formulação farmacêutica compreendendo temozolomida, processo para a produção da mesma, bem como artigo fabricado contendo pó liofilizado compreendendo temozolomida
US7449488B2 (en) 2002-06-04 2008-11-11 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7161003B1 (en) 2002-09-04 2007-01-09 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7205308B2 (en) 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
TW200536536A (en) 2004-02-25 2005-11-16 Schering Corp Pyrazolotriazines as kinase inhibitors
CN101098696A (zh) * 2004-11-09 2008-01-02 先灵公司 基于患者mgmt水平来治疗癌症的替莫唑胺的改进给药方案
WO2006060464A1 (en) * 2004-12-02 2006-06-08 Schering Corporation Methods of using temozolomide formulation intrathecally in the treatment of cancers
CN101321759A (zh) 2005-10-06 2008-12-10 先灵公司 作为蛋白激酶抑制剂的吡唑并嘧啶化合物
AU2006299338A1 (en) 2005-10-06 2007-04-12 Merck Sharp & Dohme Corp. Pyrazolopyrimidines as protein kinase inhibitors
BRPI0616985B1 (pt) 2005-10-06 2021-10-26 Merck Sharp & Dohme Corp. Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto
US7645762B2 (en) 2005-10-06 2010-01-12 Schering Corporation Substituted pyrazolo[1,5-a] pyrimidines as protein kinase inhibitors

Also Published As

Publication number Publication date
EP2157972A1 (en) 2010-03-03
TW200845962A (en) 2008-12-01
NZ580982A (en) 2012-05-25
EP2409700A1 (en) 2012-01-25
CN101678002A (zh) 2010-03-24
AU2008251921A1 (en) 2008-11-20
MX2009012054A (es) 2009-11-19
WO2008140724A1 (en) 2008-11-20
CA2686848A1 (en) 2008-11-20
BRPI0823416A2 (pt) 2015-06-16
JP2010526809A (ja) 2010-08-05
ZA200907834B (en) 2011-04-28
AU2008251921A2 (en) 2010-01-07
US20100210700A1 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
CL2008001332A1 (es) Uso de temozolomida para preparar un medicamento util para el tratamiento de un desorden proliferativo.
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
EP4233861A3 (en) Compositions for treatment of essential tremor
RU2016105581A (ru) Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
SG10201805552PA (en) Sodium channel modulators for the treatment of pain and diabetes
UA113165C2 (xx) Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
AR086356A1 (es) Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2
AU2012340752A8 (en) Implantable solid-liquid drug delivery apparatus, formulations, and methods of use
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112014015482A8 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
MX2013004406A (es) Tratamiento de diabetes mellitus usando inyecciones de insulina administradas con intervalos variables de inyeccion.
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
TNSN07419A1 (en) Methods for treating drug resistant cancer
BR112017006272A2 (pt) composição farmacêutica para tratar colite ulcerativa.
AR043259A1 (es) Metodo para el tratamiento de insuficiencia cardiaca severa y medicamento para ello
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
RU2016114098A (ru) Новое производное аналога инсулина
BR112014002885A2 (pt) uso de composto orgânico para o tratamento da síndrome de noonan
RU2015112121A (ru) Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)
AR079000A1 (es) Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas
EP4389218A3 (en) Composition for treating joint disease and kit containing same
NZ604009A (en) A combination composition comprising ibuprofen and paracetamol
AR074470A1 (es) Compuesto de amida del acido ciclopropanocarboxilico, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de diabetes